CXCR4 and AL amyloidosis: Here, BMS-936564 / MDX1338 also called Ulocuplumab belongs to the most promising candidates and is currently under investigation in clinical phase I, including a phase Ib/II trial in multiple myeloma, combining the anti-CXCR4 antibody with lenalidomide or bortezomib plus dexamethasone, showing encouraging clinical activity [94, 95].